Antibody-enabled small-molecule drug discovery
暂无分享,去创建一个
[1] C. Murray,et al. The rise of fragment-based drug discovery. , 2009, Nature chemistry.
[2] Rob Leurs,et al. Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis. , 2011, Journal of the American Chemical Society.
[3] Colin L Masters,et al. Crystal Structure of the Amyloid-β p3 Fragment Provides a Model for Oligomer Formation in Alzheimer's Disease , 2011, The Journal of Neuroscience.
[4] C. Wstermeire. Structure at 2.7 A resolution of the Paracococcus dendrificans two-subunit cytochrome c oxidase coupled with an antibody Fv fragment , 1997 .
[5] S. Sidhu,et al. Two-state selection of conformation-specific antibodies , 2009, Proceedings of the National Academy of Sciences.
[6] A. Christopoulos. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery , 2002, Nature Reviews Drug Discovery.
[7] W. Delano. Unraveling hot spots in binding interfaces: progress and challenges. , 2002, Current opinion in structural biology.
[8] W. Hol,et al. Structures of a key interaction protein from the Trypanosoma brucei editosome in complex with single domain antibodies. , 2010, Journal of structural biology.
[9] T. Tuschl,et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.
[10] A. Cattaneo,et al. In vivo selection of intrabodies specifically targeting protein-protein interactions: a general platform for an "undruggable" class of disease targets. , 2008, Journal of biotechnology.
[11] Jonathan Goldberg,et al. Crystal structure of ARF1*Sec7 complexed with Brefeldin A and its implications for the guanine nucleotide exchange mechanism. , 2003, Molecular cell.
[12] Marko Hyvönen,et al. Targeting protein-protein interactions and fragment-based drug discovery. , 2012, Topics in current chemistry.
[13] P. Hajduk,et al. NMR-based screening in drug discovery , 1999, Quarterly Reviews of Biophysics.
[14] R. Webster,et al. Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex. , 1994, European journal of biochemistry.
[15] Holger Gohlke,et al. Targeting protein-protein interactions with small molecules: challenges and perspectives for computational binding epitope detection and ligand finding. , 2006, Current medicinal chemistry.
[16] Lode Wyns,et al. Crystal Structure of the Intrinsically Flexible Addiction Antidote MazE* , 2003, Journal of Biological Chemistry.
[17] C. Sachse,et al. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils , 2007, Proceedings of the National Academy of Sciences.
[18] Hartmut Michel,et al. Structure at 2.8 Å resolution of cytochrome c oxidase from Paracoccus denitrificans , 1995, Nature.
[19] C. Duyckaerts,et al. Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. , 2009, Molecular immunology.
[20] Christopher M. Dobson,et al. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme , 2003, Nature.
[21] S. Iwata,et al. G protein-coupled receptor inactivation by an allosteric inverse-agonist antibody , 2011, Nature.
[22] D. Kirchhofer,et al. Structural and mechanistic insight into how antibodies inhibit serine proteases. , 2010, The Biochemical journal.
[23] A. Koide,et al. Toward chaperone‐assisted crystallography: Protein engineering enhancement of crystal packing and X‐ray phasing capabilities of a camelid single‐domain antibody (VHH) scaffold , 2008, Protein science : a publication of the Protein Society.
[24] J. Boonstra,et al. The development of activating and inhibiting camelid VHH domains against human protein kinase C epsilon. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[25] C. Dobson,et al. Structure and properties of a complex of α-synuclein and a single-domain camelid antibody. , 2010, Journal of molecular biology.
[26] Philip J. Hajduk,et al. Fragment-based lead discovery: challenges and opportunities , 2011, J. Comput. Aided Mol. Des..
[27] J. Weissenbach,et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.
[28] T. Rabbitts,et al. Intracellular antibodies and challenges facing their use as therapeutic agents. , 2003, Trends in molecular medicine.
[29] Annik Prat,et al. The biology and therapeutic targeting of the proprotein convertases , 2012, Nature Reviews Drug Discovery.
[30] J. Changeux,et al. Allosteric proteins and cellular control systems. , 1963, Journal of molecular biology.
[31] L. Wyns,et al. Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic β2-microglobulin variant , 2011, Proceedings of the National Academy of Sciences of the United States of America.
[32] R. Wallace. Novel targets for drug discovery , 1996 .
[33] H. Michel,et al. Structure at 2.7 A resolution of the Paracoccus denitrificans two-subunit cytochrome c oxidase complexed with an antibody FV fragment. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[34] Walter Huber,et al. Fragment-Based Screening Using Surface Plasmon Resonance Technology , 2009, Journal of biomolecular screening.
[35] R. Stevens,et al. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. , 2010, Journal of molecular biology.
[36] J. Steyaert,et al. Constraining enzyme conformational change by an antibody leads to hyperbolic inhibition. , 2011, Journal of molecular biology.
[37] J. Steyaert,et al. Substrate-dependent modulation of enzyme activity by allosteric effector antibodies. , 2009, Biochimica et biophysica acta.
[38] G. Air,et al. Distribution of sequence differences in influenza N9 neuraminidase of tern and whale viruses and crystallization of the whale neuraminidase complexed with antibodies. , 1987, Virology.
[39] Matthew P Jacobson,et al. Turning a protein kinase on or off from a single allosteric site via disulfide trapping , 2011, Proceedings of the National Academy of Sciences.
[40] A. Kossiakoff,et al. Allosteric Control of Ligand Binding Affinity Using Engineered Conformation-Specific Effector Proteins , 2010, Nature Structural &Molecular Biology.
[41] Anthony M Giannetti,et al. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance. , 2011, Methods in enzymology.
[42] D. Bartel,et al. A portable RNA sequence whose recognition by a synthetic antibody facilitates structural determination , 2010, Nature Structural &Molecular Biology.
[43] S. Rasmussen,et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.
[44] R. Nussinov,et al. Is allostery an intrinsic property of all dynamic proteins? , 2004, Proteins.
[45] Peter M Fischer,et al. Small-molecule inhibitors of MDM2 as new anticancer therapeutics. , 2010, Seminars in cancer biology.
[46] T. Blundell,et al. Structural biology in fragment-based drug design. , 2010, Current opinion in structural biology.
[47] Jan Steyaert,et al. Crystal structure of the N-terminal domain of the secretin GspD from ETEC determined with the assistance of a nanobody. , 2009, Structure.
[48] C. Rudin,et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] A. Lawson,et al. High-Throughput Screening for High Affinity Antibodies , 2009 .
[50] M Kahn,et al. Design and synthesis of a mimetic from an antibody complementarity-determining region. , 1991, Science.
[51] P. Hajduk,et al. Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.
[52] J. Maynard,et al. Conversion of scFv peptide-binding specificity for crystal chaperone development. , 2011, Protein engineering, design & selection : PEDS.
[53] Christopher L. McClendon,et al. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.
[54] Razvan C. Bunescu,et al. Consolidating the set of known human protein-protein interactions in preparation for large-scale mapping of the human interactome , 2005, Genome Biology.
[55] James R Horn,et al. Allosteric inhibition through core disruption. , 2004, Journal of molecular biology.
[56] P. Hajduk,et al. A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.
[57] W. Hol,et al. Nanobody-aided structure determination of the EpsI:EpsJ pseudopilin heterodimer from Vibrio vulnificus. , 2009, Journal of structural biology.
[58] R. MacKinnon,et al. Chemistry of ion coordination and hydration revealed by a K+ channel–Fab complex at 2.0 Å resolution , 2001, Nature.
[59] Sarah Crunkhorn. Trial watch: PCSK9 antibody reduces LDL cholesterol , 2012, Nature Reviews Drug Discovery.
[60] Michelle R. Arkin,et al. Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.
[61] H. Jhoti,et al. Fragment-based drug discovery using rational design. , 2007, Ernst Schering Foundation symposium proceedings.
[62] Magnus Björsne,et al. Label-Free Primary Screening and Affinity Ranking of Fragment Libraries Using Parallel Analysis of Protein Panels , 2008, Journal of biomolecular screening.
[63] J. Tait,et al. Challenges and opportunities. , 1996, Journal of psychiatric and mental health nursing.
[64] Jacqueline Cherfils,et al. Structure-based discovery of an inhibitor of Arf activation by Sec7 domains through targeting of protein–protein complexes , 2007, Proceedings of the National Academy of Sciences.
[65] M. Rossmann,et al. Preparation and crystallization of a human immunodeficiency virus p24-Fab complex. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[66] D. Barford,et al. Conformation-Sensing Antibodies Stabilize the Oxidized Form of PTP1B and Inhibit Its Phosphatase Activity , 2011, Cell.
[67] D. Kirchhofer,et al. Unraveling the allosteric mechanism of serine protease inhibition by an antibody. , 2009, Structure.